ICON Public (NASDAQ:ICLR) Price Target Increased to $349.00 by Analysts at TD Cowen

ICON Public (NASDAQ:ICLR) had its price target upped by TD Cowen from $343.00 to $349.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other analysts also recently issued reports on the company. Barclays lifted their price target on ICON Public from $325.00 to $355.00 and gave the company an overweight rating in a research report on Friday, February 23rd. Evercore ISI lifted their price target on ICON Public from $325.00 to $350.00 and gave the company an outperform rating in a research report on Friday, February 23rd. Truist Financial lifted their price target on ICON Public from $357.00 to $367.00 and gave the company a buy rating in a research report on Friday, February 23rd. Mizuho reiterated a buy rating and set a $346.00 price target on shares of ICON Public in a research report on Thursday, April 4th. Finally, Robert W. Baird lifted their price target on ICON Public from $362.00 to $363.00 and gave the company an outperform rating in a research report on Friday. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, ICON Public has an average rating of Moderate Buy and a consensus price target of $321.64.

ICON Public Trading Up 2.7 %

Shares of ICLR opened at $308.31 on Friday. The business has a 50-day moving average of $318.89 and a 200 day moving average of $282.81. ICON Public has a fifty-two week low of $181.92 and a fifty-two week high of $344.77. The firm has a market cap of $25.44 billion, a P/E ratio of 37.51, a price-to-earnings-growth ratio of 1.42 and a beta of 1.15. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.13. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.08 billion. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. As a group, research analysts forecast that ICON Public will post 14.4 EPS for the current year.

Institutional Trading of ICON Public

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bruce G. Allen Investments LLC bought a new stake in ICON Public in the fourth quarter valued at approximately $25,000. Riverview Trust Co bought a new stake in ICON Public in the first quarter valued at approximately $31,000. Livelsberger Financial Advisory bought a new stake in ICON Public in the fourth quarter valued at approximately $29,000. Pinnacle Bancorp Inc. lifted its position in ICON Public by 110.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 55 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in ICON Public in the fourth quarter valued at approximately $37,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.